

3. (Amended) An isolated expression plasmid comprising the polynucleotide of claim 32.

C<sub>1</sub>  
4. (Amended) An isolated transformant that is transformed with the expression plasmid of claim 3.

7. (Amended) A pharmaceutical composition that comprises as an active ingredient the polynucleotide of claim 32.

C<sub>2</sub>  
8. (Amended) A pharmaceutical composition for treating or preventing tumors, which comprises as an active ingredient the polynucleotide of claim 32.

C<sub>3</sub> mb  
PR. 0  
+  
process  
19. (Amended) An isolated nucleic acid that encodes a tumor antigen protein, wherein said tumor antigen protein gives rise to peptide fragments which are encoded by the polypeptide of claim 32, or are produced by the process of claim 5, and bind to an HLA antigen and are recognized by cytotoxic T lymphocytes. polynucleotides

C<sub>4</sub>  
21. (Amended) A pharmaceutical composition for treating or preventing tumors, which comprises as an active ingredient the recombinant polynucleotide of claim 33.

C5 23. (Amended) An antigen-presenting cell wherein a complex between an HLA antigen and the tumor antigen peptide or the derivative thereof according to claim 9 is presented on the surface of a cell having antigen-presenting ability, which cell is isolated from a tumor patient.

C6 25. (Amended) A pharmaceutical composition for treating tumors, which comprises as an active ingredient the antigen-presenting cell of claim 23.

26. (Amended) A cyclotoxic T lymphocyte that specifically recognizes a complex between an HLA antigen and the tumor antigen peptide or derivative thereof according to claim 9.

✓  
Please add the following claims:

--32. An isolated polynucleotide selected from the group consisting of:

C7 (a) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2,

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1, and

EN D2 (c) a polynucleotide which hybridizes with a polynucleotide of any one of (a) to (b), under stringent hybridization conditions

comprising 6xSSC, 50% formamide, and 0.5% SDS and a temperature of 42°C,

wherein said polynucleotide encodes a tumor antigen protein, and peptide fragments thereof bind to an HLA antigen and are recognized by cytotoxic T lymphocytes.

33. An isolated recombinant nucleic acid comprising at least one of the nucleic acids of claim 19.

34. An isolated expression plasmid comprising the recombinant nucleic acid of claim 33.--